Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1402-1411
Open Access | Times Cited: 987

Showing 1-25 of 987 citing articles:

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 18, pp. 1637-1648
Open Access | Times Cited: 635
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 953-953
Open Access | Times Cited: 408
Increased global integration in the brain after psilocybin therapy for depression
Richard E. Daws, Christopher Timmermann, Bruna Giribaldi, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 844-851
Open Access | Times Cited: 303
Novel and emerging treatments for major depression
Steven Marwaha, Edward Palmer, Trisha Suppes, et al.
The Lancet (2022) Vol. 401, Iss. 10371, pp. 141-153
Open Access | Times Cited: 297
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 293
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
Manoj K. Doss, Michal Považan, Monica D. Rosenberg, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 227
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Rafael Moliner, Mykhailo Girych, Cecilia A. Brunello, et al.
Nature Neuroscience (2023) Vol. 26, Iss. 6, pp. 1032-1041
Open Access | Times Cited: 223
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
Robin von Rotz, Eva Maria Schindowski, Johannes Jungwirth, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101809-101809
Open Access | Times Cited: 220
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 219
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Charles L. Raison, Gerard Sanacora, Joshua D. Woolley, et al.
JAMA (2023) Vol. 330, Iss. 9, pp. 843-843
Open Access | Times Cited: 219
Structure-based discovery of nonhallucinogenic psychedelic analogs
Dongmei Cao, Jing Yu, Huan Wang, et al.
Science (2022) Vol. 375, Iss. 6579, pp. 403-411
Closed Access | Times Cited: 209
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
Anat Levit, Danielle N. Confair, Kuglae Kim, et al.
Nature (2022) Vol. 610, Iss. 7932, pp. 582-591
Open Access | Times Cited: 174
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 173
Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Friederike Holze, Peter Gasser, Felix Müller, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 3, pp. 215-223
Closed Access | Times Cited: 170
The neural basis of psychedelic action
Alex C. Kwan, David E. Olson, Katrin H. Preller, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1407-1419
Closed Access | Times Cited: 166
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
Mario de la Fuente Revenga, Bohan Zhu, Christopher A. Guevara, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109836-109836
Open Access | Times Cited: 147
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Laura Ley, Felix Müller, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 6, pp. 1180-1187
Open Access | Times Cited: 144
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 140
The promises and perils of psychedelic pharmacology for psychiatry
Tristan McClure‐Begley, Bryan L. Roth
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 463-473
Closed Access | Times Cited: 139
Psychedelics reopen the social reward learning critical period
Romain Nardou, Edward J. Sawyer, Young Jun Song, et al.
Nature (2023) Vol. 618, Iss. 7966, pp. 790-798
Open Access | Times Cited: 138
Human brain effects of DMT assessed via EEG-fMRI
Christopher Timmermann, Leor Roseman, Sharad Haridas, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 13
Open Access | Times Cited: 129
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
A. Becker, Friederike Holze, Tanja Grandinetti, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 886-895
Open Access | Times Cited: 128
Psychedelics alter metaphysical beliefs
Christopher Timmermann, Hannes Kettner, Chris Letheby, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 127
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 125
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 114
Page 1 - Next Page

Scroll to top